Celldex Therapeutics Inc. (CLDX)
NASDAQ: CLDX
· Real-Time Price · USD
20.40
-0.86 (-4.05%)
At close: Jun 16, 2025, 3:59 PM
20.16
-1.15%
After-hours: Jun 16, 2025, 07:22 PM EDT
-4.05% (1D)
| Bid | 19.71 |
| Market Cap | 1.35B |
| Revenue (ttm) | 7.56M |
| Net Income (ttm) | -178.85M |
| EPS (ttm) | -2.7 |
| PE Ratio (ttm) | -7.56 |
| Forward PE | -5.12 |
| Analyst | Buy |
| Ask | 20.97 |
| Volume | 1,257,353 |
| Avg. Volume (20D) | 922,006 |
| Open | 21.43 |
| Previous Close | 21.26 |
| Day's Range | 19.87 - 21.43 |
| 52-Week Range | 14.40 - 47.00 |
| Beta | 1.14 |
About CLDX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CLDX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CLDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts8 months ago
-12.06%
Celldex Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
10 months ago
-8.45%
Celldex Therapeutics shares are trading lower. The company announced topline results from its Phase 2 clinical trial of barzolvolimab.
